Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442507 | 0.88 | BRAF (0.53) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5448592 | 0.85 | BRAF (0.53) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5442516 | 0.85 | BRAF (0.52) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5442557 | 0.81 | BRAF (0.50) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5216137 | 0.81 | KDM4E (0.66) | BRAFCYP2C9RAF1YES1KDR | |
| SCHEMBL5004904 | 0.77 | BRAF (0.76) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL18196115 | 0.75 | BRAF (0.75) | BRAFCYP2C9 | |
| SCHEMBL1697890 | 0.75 | BRAF (0.59) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697892 | 0.73 | BRAF (0.56) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5007890 | 0.73 | BRAF (0.71) | BRAFCYP2C9RAF1YES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ARAF, BRAF, RAF1 | BRAF 2/4885CYP2C9 1730/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.